Sara Silbert
Biographic Data
| ID | 8306498 |
|---|---|
| NAME | Sara Silbert |
| GIVEN NAMES | Sara |
| FAMILY NAME | Silbert |
| SIGNATURE | SILBERT S |
| AFFILIATIONS | University of Michigan |
| ORCID | 0000-0002-2746-9410 |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2019 |
| LATEST PUBLICATION YEAR | 2019 |
| H-INDEX | 0 |
How Should We Determine the Value of CAR T-Cell Therapy
In 2017, the US Food and Drug Administration approved the first chimeric antigen receptor (CAR) T-cell therapies for patients with relapsed or refractory B-cell leukemia and selected B-cell lymphomas. This novel form of cellular immunotherapy creates a "living drug" that effectively reprograms a patient's T cells to target specific antigens on the surface of a tumor. The therapy has high response rates in patients with refractory disease, althoug…
No prominent works on this page.
How Should We Determine the Value of CAR T-Cell Therapy
In 2017, the US Food and Drug Administration approved the first chimeric antigen receptor (CAR) T-cell therapies for patients with relapsed or refractory B-cell leukemia and selected B-cell lymphomas. This novel form of cellular immunotherapy creates a "living drug" that effectively reprograms a patient's T cells to target specific antigens on the surface of a tumor. The therapy has high response rates in patients with refractory disease, althoug…
Antigen (1 work) · Biology (1 work) · Biomedical Ethics and Regulation (1 work) · Cancer Research (1 work) · CAR-T cell therapy research (1 work) · Cell (1 work) · Cell therapy (1 work) · Chimeric antigen receptor (1 work) · Disease (1 work) · Drug (1 work)